Specialty Pharmacy

PaxVax, an independent specialty vaccine company, is developing the prophylaxis.

Tisagenlecleucel (Kymriah, Novartis) is now approved for the treatment of diffuse large B-cell (DLBCL) lymphoma, as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Trametinib plus dabrafenib is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection.

The study found a calculable personal genetic risk score that was applicable to approximately 60,000 patients.

Although current guidelines recommend that HIV primary care intervals do not exceed 6 months, gaps in care up to 9 months do not worsen viral load for patients.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Half of all HAE drug expenses were billed through the pharmacy benefit and half through the medical benefit.

HIV targets and disables a pathway involved in blocking viral activity and clearing infection.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ali McBride, PharmD, MS, BCPS, BCOP, explains what strategies can help ensure patients are adherent to oral chemotherapy regimens.

Poor study design and reporting in animal research compromises the ethical review of proposed human drug trials.

A synthetic bridged nucleic acid was found to greatly improve the accuracy of gene-editing technology, which could potentially lead to new therapies for genetic diseases.

People living with HIV are at elevated risk for hyponatremia, the most common electrolyte disorder seen in hospitals.

The new method indexes thousands of cells simultaneously and could potentially improve understanding of various diseases at a molecular level.

The findings suggest that a patient’s diet may impact their ability to combat head and neck cancer.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacy Director at Florida Cancer Speciality, discusses interventions aimed at reducing the waste and cost of expensive oral chemotherapy treatments.

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

Unintentional weight loss may allow physicians to detect cancer sooner.

Burosumab (Crysvita, Ultragenyx) is the first treatment approved for x-linked hypophosphatemia in adults and children ages 1 and older.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, speaks about how specialty pharmacies have to adjust their operations to meet the needs of their patients.

Following the approval of voretigene neparvovec, new treatments are on the horizon for retinitis pigmentosa.

When deciding to include a pharmacy in a distribution network, a manufacturer will look for factors that positively differentiate the pharmacy, as well as factors that will likely help the target patient population.

Top news of the week from Specialty Pharmacy Times.

Several barriers to value-based care exist, including finances and cost, meaning both the financial investments required by small- and mid-sized provider groups and the size of corresponding incentives.

Patients with severe hemophilia are at the highest risk for spontaneous bleeds, therefore are associated with the highest costs.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.